Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avantor, Inc.AVTR · Entity 3546 | Director | May 08, 2025 | May 12, 2025 |
| Evelo Biosciences, Inc.EVLO · Entity 108468 | Director | June 08, 2023 | June 12, 2023 |
| Moderna, Inc.MRNA · Entity 2025 | Chief Operating Officer | October 05, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avantor, Inc.
Report date May 08, 2025 · Filed May 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,480 |
Reported balance
After 2025-05-08 transaction · row 1
1 source rowRow 1 · 2025-05-08 · Grant · Acquired 17,100 · Balance 65,480 F1: Reflects a grant of restricted stock units that vests on May 08, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units that vests on May 08, 2026.
Evelo Biosciences, Inc.
Report date June 08, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.11 · Expires 2033-06-08 | Direct | 20,000 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 20,000 · Balance 20,000 F1: The option vests on the earlier of June 8, 2024 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of June 8, 2024 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant.
Moderna, Inc.
Report date October 05, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,000 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 125,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2022 Filed Aug 11, 2022 20:57 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-020832 · form4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 20:57 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 204 | $173.66 | $35,427.25 |
DisclosureSEC source: 0001127602-22-020832 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,598 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 20:57 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 435 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020832 · form4.xml · derivative · entry 5 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,353 Underlying: Common Stock · 435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 20:57 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-020832 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:38 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-020582 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:38 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $167.99 | $335,980.00 |
DisclosureSEC source: 0001127602-22-020582 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,367 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:38 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-020582 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 20:47 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-019936 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 20:47 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $161.00 | $322,000.00 |
DisclosureSEC source: 0001127602-22-019936 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,367 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 20:47 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-019936 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 20:40 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-019665 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 20:40 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $167.00 | $334,000.00 |
DisclosureSEC source: 0001127602-22-019665 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,367 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 20:40 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-019665 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-019348 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $168.88 | $337,760.00 |
DisclosureSEC source: 0001127602-22-019348 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,367 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:32 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-019348 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 20:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-019117 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 20:04 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $154.85 | $309,700.00 |
DisclosureSEC source: 0001127602-22-019117 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,367 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 20:04 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-019117 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:59 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-018745 · form4.xml · derivative · entry 7 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:59 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-018745 · form4.xml · derivative · entry 6 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:59 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-018745 · form4.xml · derivative · entry 5 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:59 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 6,000 | $150.00 | $900,000.00 |
DisclosureSEC source: 0001127602-22-018745 · form4.xml · nonDerivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,367 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:59 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-018745 · form4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:59 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-018745 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:59 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-018745 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 16:35 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001694665-22-000096 · wf-form4_165515252492270.xml · derivative · entry 1 Andres Juan · CIK 0001760670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests on the earlier of June 9, 2023 and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 629 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001127602-22-017229 · form4.xml · derivative · entry 13 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 629 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-017229 · form4.xml · derivative · entry 12 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-017229 · form4.xml · derivative · entry 11 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-017229 · form4.xml · derivative · entry 10 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-017229 · form4.xml · derivative · entry 9 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,025 Underlying: Common Stock · 2,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,371 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-22-017229 · form4.xml · derivative · entry 8 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,025 Underlying: Common Stock · 1,371 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 10,000 | $150.00 | $1,500,000.00 |
DisclosureSEC source: 0001127602-22-017229 · form4.xml · nonDerivative · entry 7 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,367 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 629 | $14.22 | $8,944.38 |
DisclosureSEC source: 0001127602-22-017229 · form4.xml · nonDerivative · entry 6 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-017229 · form4.xml · nonDerivative · entry 5 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-017229 · form4.xml · nonDerivative · entry 4 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-017229 · form4.xml · nonDerivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $20.93 | $41,860.00 |
DisclosureSEC source: 0001127602-22-017229 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,371 | $20.93 | $28,695.03 |
DisclosureSEC source: 0001127602-22-017229 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 21:17 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 749 | $145.40 | $108,904.45 |
DisclosureSEC source: 0001127602-22-016216 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,367 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:17 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,807 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-016216 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,655 Underlying: Common Stock · 1,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. F3 · derivative.expiration_date: 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 21:17 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,807 | $135.80 | $245,390.60 |
DisclosureSEC source: 0001127602-22-016216 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 12, 2022 Filed May 16, 2022 22:14 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 6,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001722482-22-000125 · wf-form4_165273923846993.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,095 F1 · kind: Reflects a grant of restricted stock units that vests on May 12, 2023. Read SEC document |
| May 10, 2022 Filed May 11, 2022 20:24 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 195 | $133.71 | $26,074.19 |
DisclosureSEC source: 0001127602-22-014146 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,309 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 09, 2022 Filed May 11, 2022 20:24 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 435 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-014146 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,788 Underlying: Common Stock · 435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 9, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 09, 2022 Filed May 11, 2022 20:24 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 435 | $134.40 | $58,464.00 |
DisclosureSEC source: 0001127602-22-014146 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 04, 2022 Filed May 6, 2022 20:06 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001127602-22-013640 · form4.xml · derivative · entry 3 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 629 Underlying: Common Stock · 2,000 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| May 04, 2022 Filed May 6, 2022 20:06 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 2,000 | $153.23 | $306,460.00 |
DisclosureSEC source: 0001127602-22-013640 · form4.xml · nonDerivative · entry 2 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,069 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
| May 04, 2022 Filed May 6, 2022 20:06 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,000 | $14.22 | $28,440.00 |
DisclosureSEC source: 0001127602-22-013640 · form4.xml · nonDerivative · entry 1 Andres Juan · CIK 0001760670 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.